Trimethoprim-sulfamethoxazole revisited

Philip A. Masters, Thomas A. O'Bryan, John Zurlo, Debra Q. Miller, Nirmal Joshi

Research output: Contribution to journalReview article

136 Citations (Scopus)

Abstract

During the past 3 decades, the combination of trimethoprim and sulfamethoxazole has occupied a central role in the treatment of various commonly encountered infections and has also been particularly useful for several specific clinical conditions. However, changing resistance patterns and the introduction of newer broad-spectrum antibiotics have led to the need to carefully redefine the appropriate use of this agent in clinical practice. While trimethoprim-sulfamethoxazole's traditional role as empirical therapy for several infections has been modified by increasing resistance, it remains a highly useful alternative to the new generation of expanded-spectrum agents if resistance patterns and other clinical variables are carefully considered. It also seems to have an increasing role as a cost-effective pathogen-directed therapy with the potential to decrease or delay development of resistance to newer antibiotics used for empirical treatment. In addition, trimethoprim-sulfamethoxazole continues to be the drug of choice for several clinical indications.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalArchives of Internal Medicine
Volume163
Issue number4
DOIs
StatePublished - Feb 24 2003

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Anti-Bacterial Agents
Infection
Costs and Cost Analysis
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Masters, P. A., O'Bryan, T. A., Zurlo, J., Miller, D. Q., & Joshi, N. (2003). Trimethoprim-sulfamethoxazole revisited. Archives of Internal Medicine, 163(4), 402-410. https://doi.org/10.1001/archinte.163.4.402
Masters, Philip A. ; O'Bryan, Thomas A. ; Zurlo, John ; Miller, Debra Q. ; Joshi, Nirmal. / Trimethoprim-sulfamethoxazole revisited. In: Archives of Internal Medicine. 2003 ; Vol. 163, No. 4. pp. 402-410.
@article{9132028e7f364e5b9b69aba891c42a18,
title = "Trimethoprim-sulfamethoxazole revisited",
abstract = "During the past 3 decades, the combination of trimethoprim and sulfamethoxazole has occupied a central role in the treatment of various commonly encountered infections and has also been particularly useful for several specific clinical conditions. However, changing resistance patterns and the introduction of newer broad-spectrum antibiotics have led to the need to carefully redefine the appropriate use of this agent in clinical practice. While trimethoprim-sulfamethoxazole's traditional role as empirical therapy for several infections has been modified by increasing resistance, it remains a highly useful alternative to the new generation of expanded-spectrum agents if resistance patterns and other clinical variables are carefully considered. It also seems to have an increasing role as a cost-effective pathogen-directed therapy with the potential to decrease or delay development of resistance to newer antibiotics used for empirical treatment. In addition, trimethoprim-sulfamethoxazole continues to be the drug of choice for several clinical indications.",
author = "Masters, {Philip A.} and O'Bryan, {Thomas A.} and John Zurlo and Miller, {Debra Q.} and Nirmal Joshi",
year = "2003",
month = "2",
day = "24",
doi = "10.1001/archinte.163.4.402",
language = "English (US)",
volume = "163",
pages = "402--410",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "4",

}

Masters, PA, O'Bryan, TA, Zurlo, J, Miller, DQ & Joshi, N 2003, 'Trimethoprim-sulfamethoxazole revisited', Archives of Internal Medicine, vol. 163, no. 4, pp. 402-410. https://doi.org/10.1001/archinte.163.4.402

Trimethoprim-sulfamethoxazole revisited. / Masters, Philip A.; O'Bryan, Thomas A.; Zurlo, John; Miller, Debra Q.; Joshi, Nirmal.

In: Archives of Internal Medicine, Vol. 163, No. 4, 24.02.2003, p. 402-410.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Trimethoprim-sulfamethoxazole revisited

AU - Masters, Philip A.

AU - O'Bryan, Thomas A.

AU - Zurlo, John

AU - Miller, Debra Q.

AU - Joshi, Nirmal

PY - 2003/2/24

Y1 - 2003/2/24

N2 - During the past 3 decades, the combination of trimethoprim and sulfamethoxazole has occupied a central role in the treatment of various commonly encountered infections and has also been particularly useful for several specific clinical conditions. However, changing resistance patterns and the introduction of newer broad-spectrum antibiotics have led to the need to carefully redefine the appropriate use of this agent in clinical practice. While trimethoprim-sulfamethoxazole's traditional role as empirical therapy for several infections has been modified by increasing resistance, it remains a highly useful alternative to the new generation of expanded-spectrum agents if resistance patterns and other clinical variables are carefully considered. It also seems to have an increasing role as a cost-effective pathogen-directed therapy with the potential to decrease or delay development of resistance to newer antibiotics used for empirical treatment. In addition, trimethoprim-sulfamethoxazole continues to be the drug of choice for several clinical indications.

AB - During the past 3 decades, the combination of trimethoprim and sulfamethoxazole has occupied a central role in the treatment of various commonly encountered infections and has also been particularly useful for several specific clinical conditions. However, changing resistance patterns and the introduction of newer broad-spectrum antibiotics have led to the need to carefully redefine the appropriate use of this agent in clinical practice. While trimethoprim-sulfamethoxazole's traditional role as empirical therapy for several infections has been modified by increasing resistance, it remains a highly useful alternative to the new generation of expanded-spectrum agents if resistance patterns and other clinical variables are carefully considered. It also seems to have an increasing role as a cost-effective pathogen-directed therapy with the potential to decrease or delay development of resistance to newer antibiotics used for empirical treatment. In addition, trimethoprim-sulfamethoxazole continues to be the drug of choice for several clinical indications.

UR - http://www.scopus.com/inward/record.url?scp=0037463683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037463683&partnerID=8YFLogxK

U2 - 10.1001/archinte.163.4.402

DO - 10.1001/archinte.163.4.402

M3 - Review article

C2 - 12588198

AN - SCOPUS:0037463683

VL - 163

SP - 402

EP - 410

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 4

ER -